Fifty One Capital updated report, page-71

Yes it all sounds very persuasive indeed, although I'm not entirely convinced that, for big pharma, the barriers to entry would be quite as high as 51Capital seem to think. Those guys have great manufacturing expertise, deep pockets, and are very litigious, but hopefully, they'll like the product so much, they'll just buy the company instead.

$2,500 for a six week course of injections, without a Medicare rebate, when you can get Elmiron for around $50, seems pretty high, and, at that pricing, would exclude a lot of potential customers, who would perhaps be likely to turn to the grey market. I assume the pricing would become more reflective of production costs once it's received TGA approval, as nobody likes to read about drug companies exploiting the sick, the poor, and the uninsured (a very hot button issue in the US right now), and a good PR strategy around pricing will be a big plus going forward.

There are actually a couple of other promising OA drugs in the pipeline, including particularly APPA, (which combines two synthetic versions of plant compounds called apocynin and paeonol), although these are years away from commercialisation, if they ever get there, so right now Paradigm's PPS seems to have a good head start on everything else.

All up, it's all looking pretty good, and I'm very happy with my holdings, which I've picked up at 28c, 80c, and $1.20, and I haven't seen anything at all to cause me to rethink my positive share price expectations I'll probably just hold for now, and wait for the next dip before topping up again, and hope I don't have to kick myself too hard in a couple of weeks.